The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
|Videos|July 19, 2016
JAVELIN Trial Design and Safety Results in Gastric Cancer
Author(s)Hendrik-Tobias Arkenau, MD, PhD
Hendrik-Tobias Arkenau, MD, PhD, founding medical director, executive medical director, Sarah Cannon Research Institute UK, gives an overview of the JAVELIN trial in gastric cancer. He also discusses the safety profile of avelumab.
Advertisement
Advertisement
Related to this article
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies—yet gaps persist, and research funding uncertainty threatens future gains.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Pembrolizumab Biosimilar Candidate FYB206
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors
4
Durability of PFS and OS Benefit vs. Historical Control
5